These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

306 related articles for article (PubMed ID: 26775720)

  • 1. Programmed Death-Ligand 1 Expression in Muscle-Invasive Bladder Cancer Cystectomy Specimens and Lymph Node Metastasis: A Reliable Treatment Selection Biomarker?
    Mukherji D; Jabbour MN; Saroufim M; Temraz S; Nasr R; Charafeddine M; Assi R; Shamseddine A; Tawil AN
    Clin Genitourin Cancer; 2016 Apr; 14(2):183-7. PubMed ID: 26775720
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Concordance of PD-L1 expression in matched urothelial bladder cancer specimens.
    de Jong JJ; Stoop H; Nieboer D; Boormans JL; van Leenders GJLH
    Histopathology; 2018 Dec; 73(6):983-989. PubMed ID: 30003574
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression and prognostic utility of PD-L1 in patients with squamous cell carcinoma of the bladder.
    Owyong M; Lotan Y; Kapur P; Panwar V; McKenzie T; Lee TK; Zi X; Martin JW; Mosbah A; Abol-Enein H; Ghoneim M; Youssef RF
    Urol Oncol; 2019 Jul; 37(7):478-484. PubMed ID: 30910351
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PD-L1 expression in tumor-infiltrating lymphocytes (TILs) as an independent predictor of prognosis in patients with pN0 bladder cancer undergoing radical cystectomy.
    Murakami Y; Matsumoto K; Shimizu Y; Ikeda M; Amano N; Shimura S; Ishii D; Sato Y; Iwamura M
    Urol Oncol; 2021 Mar; 39(3):195.e15-195.e23. PubMed ID: 33071109
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The prognostic significance of PD-L1 in bladder cancer.
    Huang Y; Zhang SD; McCrudden C; Chan KW; Lin Y; Kwok HF
    Oncol Rep; 2015 Jun; 33(6):3075-84. PubMed ID: 25963805
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A reported 20-gene expression signature to predict lymph node-positive disease at radical cystectomy for muscle-invasive bladder cancer is clinically not applicable.
    van Kessel KE; van de Werken HJ; Lurkin I; Ziel-van der Made AC; Zwarthoff EC; Boormans JL
    PLoS One; 2017; 12(3):e0174039. PubMed ID: 28319171
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cancer Treatment with Anti-PD-1/PD-L1 Agents: Is PD-L1 Expression a Biomarker for Patient Selection?
    Festino L; Botti G; Lorigan P; Masucci GV; Hipp JD; Horak CE; Melero I; Ascierto PA
    Drugs; 2016 Jun; 76(9):925-45. PubMed ID: 27229745
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Programmed Death Ligand 1 (PD-L1) Tumor Expression Is Associated with a Better Prognosis and Diabetic Disease in Triple Negative Breast Cancer Patients.
    Botti G; Collina F; Scognamiglio G; Rao F; Peluso V; De Cecio R; Piezzo M; Landi G; De Laurentiis M; Cantile M; Di Bonito M
    Int J Mol Sci; 2017 Feb; 18(2):. PubMed ID: 28230773
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PD-L1 expression in tumor cells and the immunologic milieu of bladder carcinomas: a pathologic review of 165 cases.
    Davick JJ; Frierson HF; Smolkin M; Gru AA
    Hum Pathol; 2018 Nov; 81():184-191. PubMed ID: 29969606
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Programmed death ligand-1 expression is associated with poor disease free survival in salivary gland carcinomas.
    Mukaigawa T; Hayashi R; Hashimoto K; Ugumori T; Hato N; Fujii S
    J Surg Oncol; 2016 Jul; 114(1):36-43. PubMed ID: 27111278
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical significance of programmed death ligand-1 (PD-L1) in colorectal serrated adenocarcinoma.
    Zhu H; Qin H; Huang Z; Li S; Zhu X; He J; Yang J; Yu X; Yi X
    Int J Clin Exp Pathol; 2015; 8(8):9351-9. PubMed ID: 26464688
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relationship between survival outcomes and microsatellite instability, tumor infiltrating lymphocytes and programmed cell death ligand-1 expression in patients with bladder cancer and radical cystectomy.
    Tural D; Akar E; Baytekin HF; Canoglu D; Yilmaz M; Tugcu V
    J BUON; 2021; 26(5):2117-2125. PubMed ID: 34761625
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gene expression patterns through oral squamous cell carcinoma development: PD-L1 expression in primary tumor and circulating tumor cells.
    Oliveira-Costa JP; de Carvalho AF; da Silveira da GG; Amaya P; Wu Y; Park KJ; Gigliola MP; Lustberg M; Buim ME; Ferreira EN; Kowalski LP; Chalmers JJ; Soares FA; Carraro DM; Ribeiro-Silva A
    Oncotarget; 2015 Aug; 6(25):20902-20. PubMed ID: 26041877
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinicopathological analysis of PD-L1 and PD-L2 expression in pulmonary squamous cell carcinoma: Comparison with tumor-infiltrating T cells and the status of oncogenic drivers.
    Kim MY; Koh J; Kim S; Go H; Jeon YK; Chung DH
    Lung Cancer; 2015 Apr; 88(1):24-33. PubMed ID: 25662388
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Post-chemotherapy PD-L1 expression correlates with clinical outcomes in Japanese bladder cancer patients treated with total cystectomy.
    Noro D; Hatakeyama S; Yoneyama T; Hashimoto Y; Koie T; Kawaguchi T; Ohyama C
    Med Oncol; 2017 Jun; 34(6):117. PubMed ID: 28500617
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Investigation of PD-L1 Biomarker Testing Methods for PD-1 Axis Inhibition in Non-squamous Non-small Cell Lung Cancer.
    Sheffield BS; Fulton R; Kalloger SE; Milne K; Geller G; Jones M; Jacquemont C; Zachara S; Zhao E; Pleasance E; Laskin J; Jones SJ; Marra MA; Yip S; Nelson BH; Gown AM; Ho C; Ionescu DN
    J Histochem Cytochem; 2016 Oct; 64(10):587-600. PubMed ID: 27591097
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Significance of programmed cell death-ligand 1 expression and its association with survival in patients with small cell lung cancer.
    Ishii H; Azuma K; Kawahara A; Yamada K; Imamura Y; Tokito T; Kinoshita T; Kage M; Hoshino T
    J Thorac Oncol; 2015 Mar; 10(3):426-30. PubMed ID: 25384063
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PD-L1 expression in bladder cancer: Which scoring algorithm in what tissue?
    Schulz GB; Todorova R; Braunschweig T; Rodler S; Volz Y; Eismann L; Pfitzinger P; Jokisch F; Buchner A; Stief C; Mayr D; Casuscelli J
    Urol Oncol; 2021 Oct; 39(10):734.e1-734.e10. PubMed ID: 34261585
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Age and sex have no impact on expression levels of markers of immune cell infiltration and immune checkpoint pathways in patients with muscle-invasive urothelial carcinoma of the bladder treated with radical cystectomy.
    Holland BC; Sood A; Delfino K; Dynda DI; Ran S; Freed N; Alanee S
    Cancer Immunol Immunother; 2019 Jun; 68(6):991-997. PubMed ID: 30997535
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of PD-L1 Expression and Associated Tumor-Infiltrating Lymphocytes in Laryngeal Squamous Cell Carcinoma.
    Vassilakopoulou M; Avgeris M; Velcheti V; Kotoula V; Rampias T; Chatzopoulos K; Perisanidis C; Kontos CK; Giotakis AI; Scorilas A; Rimm D; Sasaki C; Fountzilas G; Psyrri A
    Clin Cancer Res; 2016 Feb; 22(3):704-13. PubMed ID: 26408403
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.